Skip to main content

Table 2 Spearman’s correlation analysis between serum δ65Cu levels and clinical parameters within the NAFLD patient cohort

From: Lighter serum copper isotopic composition in patients with early non-alcoholic fatty liver disease

 Spearman’s ρpn
BMI (kg m−2)0.030.8924
Steatosis on liver biopsy− 0.220.3421
Ballooning on liver biopsy− 0.200.3721
Inflammation on liver biopsy− 0.090.7121
NAS on liver biopsy− 0.190.4221
Fibrosis on liver biopsy− 0.130.5424
Presence of NASH (yes/no)− 0.190.3824
AST (U l−1)0.250.2324
ALT (U l−1)0.030.8924
GGT (U l−1)− 0.050.8124
Bilirubin (mg dl−1)− 0.070.7720
Glucose (mg dl−1)0.240.3020
HOMA-IR0.260.2720
HbA1c (%)0.090.7023
Diabetes (yes/no)0.190.3924
Cholesterol (mg dl−1)0.220.3917
HDL (mg dl−1)− 0.100.7117
LDL (mg dl−1)− 0.060.8019
Triglycerides (mg dl−1)− 0.160.5020
Ferritin (µg l−1)0.240.3319
Copper (µg dl−1)0.100.6918
Transferrin (mg dl−1)− 0.030.9119
Iron (µg dl−1)− 0.030.9219
  1. NAFL non-alcoholic fatty liver, NASH: non-alcoholic steatohepatitis, BMI: body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyltransferase, Hb Haemoglobin, HbA1c haemoglobin A1c, LDL low-density lipoprotein, HDL high-density lipoprotein, HOMA-IR Homeostasis Model Assessment Insulin Resistance, NAS NAFLD activity score